Youngki Yoo
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
25
Citations
147
Est. group size
—
Recurring co-author estimate
Active years
10
Publishing since 2017
Typically publishes in teams of ~10 · 10% small-team papers (≤3 authors) · across 12 venues
- High-resolution cryo-EM structures of small protein–ligand complexes near the theoretical size limit
Nature Communications · 2026
- Magnesium Transporters as Crucial Regulators of Bacterial Survival and Pathogenicity
Microorganisms · 2026
- Structure-based optimization of TEAD inhibitors: Exploring a novel subpocket near Glu347 for the treatment of NF2-mutant cancer
Bioorganic Chemistry · 2025
- Structural and functional insights of AmpG in muropeptide transport and multiple β-lactam antibiotics resistance
Nature Communications · 2025
- A Novel Antibody Against the Non–Receptor-Binding Domain Region of Middle East Respiratory Syndrome Coronavirus Spike Protein
The Journal of Infectious Diseases · 2025
- Structural insights for enhanced <scp>ROS</scp> detoxification of <scp>eKatE</scp> , a recently identified catalase in atypical <i>E. coli</i>
FEBS Journal · 2025
- Structure-Based Optimization of Tead Inhibitors: Exploring a Novel Subpocket Near Glu347 for the Treatment of Nf2-Mutant Cancer
SSRN Electronic Journal · 2024
- Oligomeric states of ASC specks regulate inflammatory responses by inflammasome in the extracellular space
Cell Death Discovery · 2023
- Correction: Oligomeric states of ASC specks regulate inflammatory responses by inflammasome in the extracellular space
Cell Death Discovery · 2023
- Supplementary Data from A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
2023
- Supplementary Data from A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
2023
- Data from A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
2023
- Data from A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
2023
- A Novel Therapeutic Anti-ErbB3, ISU104 Exhibits Potent Antitumorigenic Activity by Inhibiting Ligand Binding and ErbB3 Heterodimerization
Molecular Cancer Therapeutics · 2021
- Structural and Functional Characterizations of Cancer Targeting Nanoparticles Based on Hepatitis B Virus Capsid
International Journal of Molecular Sciences · 2021
- Nature Communications×4
- Cell Death Discovery×2
- Journal of Medicinal Chemistry×1
- Antiviral Research×1
- Journal of Experimental Botany×1
- David E.H. Fuller
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Catherine A. Tower
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Daniel B. Kearns
Biochemistry, Genetics and Molecular Biology · Indiana University
- Daniel R. Zeigler
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Michael S. VanNieuwenhze
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile